An investor account posts the figure with no study, trial or source named. Treat it as an unverified claim until data backs it up.
Recap by typeshit. Post by From Growth To Value on X.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A market research release says about 30 obesity drugs are in late-stage trials, with Lilly, Novo, Viking, Pfizer and dozens of Chinese firms in the race.
Maynooth University researchers found one Melanotan sample held just 40% of the stated peptide, and all four products had an undisclosed bulking agent.
Loading…